LeMaitre Vascular (NASDAQ:LMAT) Releases FY 2025 Earnings Guidance

Key Points

• LeMaitre Vascular has updated its FY 2025 earnings guidance, projecting earnings per share of $2.230-$2.370 and revenue between $248.0 million and $254.0 million, both higher than consensus estimates.
• The company's stock rose by 1.5% on the day of the announcement, with shares trading at $85.60 after reaching a one-year low of $71.42 and a high of $109.58.
• CEO George W. Lemaitre sold 76,868 shares of the company's stock, resulting in a 4.10% decrease in his ownership stake.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) updated its FY 2025 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of 2.230-2.370 for the period, compared to the consensus estimate of 2.154. The company issued revenue guidance of $248.0 million-$254.0 million, compared to the consensus revenue estimate of $245.5 million. LeMaitre Vascular also updated its Q3 2025 guidance to 0.540-0.590 EPS.

LeMaitre Vascular Stock Up 0.5%

LMAT stock traded up $0.49 during midday trading on Thursday, reaching $93.72. 122,340 shares of the company were exchanged, compared to its average volume of 188,692. LeMaitre Vascular has a 1-year low of $71.42 and a 1-year high of $109.58. The company has a debt-to-equity ratio of 0.48, a quick ratio of 13.83 and a current ratio of 16.49. The stock's 50-day simple moving average is $82.88 and its 200 day simple moving average is $86.73. The company has a market cap of $2.12 billion, a price-to-earnings ratio of 45.53, a price-to-earnings-growth ratio of 2.26 and a beta of 0.79.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The medical instruments supplier reported $0.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.57 by $0.03. LeMaitre Vascular had a return on equity of 13.91% and a net margin of 20.08%. The firm had revenue of $63.15 million during the quarter, compared to the consensus estimate of $62.48 million. During the same quarter in the previous year, the company posted $0.52 EPS. The business's revenue for the quarter was up 15.0% compared to the same quarter last year. On average, equities analysts forecast that LeMaitre Vascular will post 1.94 earnings per share for the current year.

LeMaitre Vascular Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 4th. Stockholders of record on Thursday, August 21st will be paid a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a dividend yield of 0.9%. The ex-dividend date is Thursday, August 21st. LeMaitre Vascular's payout ratio is presently 40.40%.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the stock. Cantor Fitzgerald boosted their price objective on shares of LeMaitre Vascular from $92.00 to $95.00 and gave the company a "neutral" rating in a research report on Wednesday. Barrington Research raised LeMaitre Vascular from a "market perform" rating to an "outperform" rating and set a $95.00 target price on the stock in a report on Wednesday. Four investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $98.00.

Insiders Place Their Bets

In other news, CEO George W. Lemaitre sold 76,868 shares of the firm's stock in a transaction on Monday, May 19th. The stock was sold at an average price of $85.79, for a total transaction of $6,594,505.72. Following the completion of the transaction, the chief executive officer directly owned 1,796,783 shares in the company, valued at $154,146,013.57. This trade represents a 4.10% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In the last quarter, insiders sold 100,000 shares of company stock worth $8,556,857. 9.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On LeMaitre Vascular

Several institutional investors have recently bought and sold shares of the company. Goldman Sachs Group Inc. increased its stake in shares of LeMaitre Vascular by 27.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 262,445 shares of the medical instruments supplier's stock worth $22,019,000 after purchasing an additional 55,804 shares during the last quarter. Millennium Management LLC grew its stake in shares of LeMaitre Vascular by 119.8% in the 1st quarter. Millennium Management LLC now owns 211,222 shares of the medical instruments supplier's stock worth $17,722,000 after acquiring an additional 115,141 shares in the last quarter. Royal Bank of Canada grew its position in LeMaitre Vascular by 1.5% during the first quarter. Royal Bank of Canada now owns 114,176 shares of the medical instruments supplier's stock valued at $9,579,000 after acquiring an additional 1,735 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of LeMaitre Vascular by 5.5% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 37,709 shares of the medical instruments supplier's stock worth $3,164,000 after purchasing an additional 1,972 shares during the period. Finally, AQR Capital Management LLC lifted its position in shares of LeMaitre Vascular by 36.4% during the first quarter. AQR Capital Management LLC now owns 27,878 shares of the medical instruments supplier's stock worth $2,339,000 after purchasing an additional 7,445 shares during the last quarter. 84.64% of the stock is currently owned by institutional investors and hedge funds.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.